Search

Author(s): Markus Huber-Lang [1, 6]; J Vidya Sarma [2, 6]; Firas S Zetoune [2, 6]; Daniel Rittirsch [2]; Thomas A Neff [2]; Stephanie R McGuire [2]; John D Lambris [3]; [...]

The history of therapeutic interventions in clinical trials for sepsis has been referred to as the "graveyard for pharmaceutical companies." That is now set to change, as research provides hope for new approaches that will be therapeutically effective in humans with sepsis., Author(s): Niels C. Riedemann [1]; Ren-Feng Guo [1]; Peter A. Ward (corresponding author) [1] There is now general agreement that sepsis and the systemic inflammatory response syndrome (SIRS) are accompanied [...]

Protective effects of C5a blockade in sepsis have been studied in rats using cecal ligation and puncture (CLP). In rats depleted of C3, a complement factor, CLP brought very short survival times, while most of those C3-intact and preimmune IgG-treated were dead in 7 days. Blood neutrophils from the latter rats had C5a, a powerful complement activation product, on surfaces.

Sepsis in humans frequently follows the body's attempt to thwart infectious agents such as bacteria, viruses and fungi. In many respects, the development of sepsis represents the harmful consequences of [...]

Author(s): Peter A Ward [1] Sepsis is a grave, often lethal condition in humans, affecting approximately 700,000 individuals in North America every year [1, 2]. Many inflammatory cells protect against [...]